drugset / Trial / NCT02716428
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in treatment-naïve participants with genotype 1b hepatitis C virus (HCV) infection.
Timeline
- Start
- 2016-05
- Primary completion
- 2017-09
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Faldaprevir | Small molecule | — | — |
| Subject | Ribavirin | Small molecule | — | — |
| Subject | TD-6450 | Unknown | — | — |